Skip to NavigationSkip to content

Sickle cell

FDA approves GBT’s Oxbryta to treat sickle cell disease

The FDA announced yesterday that it has approved Global Blood Therapeutics’ marketing application for its haemoglobin polymerisation inhibitor Oxbryta, which is used to treat sickle cell disease.

Pfizer's sickle cell drug flops at Phase 3 trial

Pfizer has said its sickle cell drug rivipansel failed to meet its primary endpoint or key secondary endpoints in a Phase 3 trial.

The experimental drug flopped in a Phase 3 RESET study of patients aged six and older with sickle cell disease who were hospitalised for a vaso-occlusive crisis (VOC), the US firm said.

Board consults on specialised services

NHS image

The NHS Commissioning Board has launched a consultation into how the NHS provides specialised services, including treatments for conditions such as cystic fibrosis (CF), sickle cell and children’s cancer.

The idea is that all patients should in future have access to the same standard of care under an identical clinical policy whatever their postcode. 

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches